Physician profile
Paul Dolinsky
NPI 1942212998
$1,013.48
in general payments reported to CMS, 2019-2025
20 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2023: $71.43 · 2024: $203 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $121.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.37 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $111.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $93.08 | 2024 | Freestyle Libre 3 |
| Amgen INC. | $80.25 | 2019 | |
| Pfizer INC. | $79.88 | 2019 | |
| Glaxosmithkline, LLC. | $59.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $46.20 | 2019 | |
| Lilly USA, LLC | $44.16 | 2023-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $41.75 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $34.04 | 2019 | |
| Sanofi Pasteur INC. | $32.03 | 2019 | |
| Medtronic, INC. | $29.38 | 2023 | Minimed 770g |
| Astrazeneca Pharmaceuticals LP | $25.79 | 2019 | |
| Sandoz INC. | $25.52 | 2024 | Hyrimoz |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $17.31 | 2019 | |
| Beta Bionics, INC. | $15.61 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Xeris Pharmaceuticals, INC. | $14.52 | 2025 | Gvoke Hypopen |
| Collegium Pharmaceutical, INC. | $11.34 | 2019 | |
| Allergan, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dolinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.